← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs
laquinimod
N07XX10
Forms & Strengths
- Oral capsules: 0.3 mg
- Oral capsules: 0.6 mg
Adult Dosing
- Multiple Sclerosis (Investigational/Phase III): 0.6 mg orally once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients under 18 years of age
Indications
- Investigated for the treatment of relapsing-remitting multiple sclerosis (RRMS)
- Investigated for Huntington's disease
Mechanism of Action
- Immunomodulatory agent acting on the central nervous system
- Reduces inflammatory cell infiltration into the CNS
- Increases brain-derived neurotrophic factor (BDNF) levels
- Exerts potential neuroprotective and anti-inflammatory effects via aryl hydrocarbon receptor activation
Contraindications
- Hypersensitivity to laquinimod or any excipients
- Pregnancy and lactation (potential teratogenic and embryotoxic risks)
- Severe hepatic impairment
Adverse Reactions
- Headache
- Abdominal pain
- Back pain
- Cough
- Elevated liver enzymes (transaminases)
- Asthenia
- Nasopharyngitis
- Venous thromboembolism (observed in clinical trials at higher doses)
Drug Interactions
- CYP3A4 inducers (may decrease laquinimod exposure)
- CYP3A4 inhibitors (may increase laquinimod exposure)
- Strong protein-bound drugs (potential for displacement interactions)
- Immunosuppressive therapies (risk of additive immune suppression)
Curated Content: Needs Vetting Before Put to Clinical Use